Loading...
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/ https://ncbi.nlm.nih.gov/pubmed/20382130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|